Other Non-Current Liabilities
Moderna Other Non-Current Liabilities decreased by 0.7% to $283M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 3.3%, from $274M to $283M. Over 5 years (FY 2020 to FY 2025), Other Non-Current Liabilities shows an upward trend with a 148.6% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
An increase may indicate rising long-term contractual obligations or deferred revenue, while a decrease suggests the settlement of these miscellaneous liabilities.
Detailed definition
This represents long-term financial obligations that do not fit into standard categories like debt or pension liabilitie...
Peer comparison
Varies widely by industry; biotech firms often have unique long-term collaboration-related liabilities.
other_non_current_liabilitiesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1M | $1M | $76M | $91M | $113M | $81M | $135M | $163M | $173M | $172M | $256M | $262M | $266M | $276M | $267M | $274M | $276M | $281M | $285M | $283M |
| QoQ Change | — | +0.0% | >999% | +19.7% | +24.2% | -28.3% | +66.7% | +20.7% | +6.1% | -0.6% | +48.8% | +2.3% | +1.5% | +3.8% | -3.3% | +2.6% | +0.7% | +1.8% | +1.4% | -0.7% |
| YoY Change | — | — | — | — | >999% | >999% | +77.6% | +79.1% | +53.1% | +112.3% | +89.6% | +60.7% | +53.8% | +60.5% | +4.3% | +4.6% | +3.8% | +1.8% | +6.7% | +3.3% |
Other Non-Current Liabilities at Other Companies
Frequently Asked Questions
- What is Moderna's other non-current liabilities?
- Moderna (MRNA) reported other non-current liabilities of $283M in Q1 2026.
- How has Moderna's other non-current liabilities changed year-over-year?
- Moderna's other non-current liabilities increased by 3.3% year-over-year, from $274M to $283M.
- What is the long-term trend for Moderna's other non-current liabilities?
- Over 5 years (2020 to 2025), Moderna's other non-current liabilities has grown at a 148.6% compound annual growth rate (CAGR), from $3M to $285M.
- What does other non-current liabilities mean?
- Miscellaneous long-term financial obligations not categorized elsewhere on the balance sheet.